Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.
Explore this paper's citation graph
Summary
It is hypothesize that new therapeutic molecules targeting VEGF and/or its receptors, such as recombinant humanized monoclonal anti-VEGF antibody (rhuMAb V EGF), may have unique activity against HER2-overexpressing breast cancers.
- Type
- article
- Published
- 2002-06-01
- Cited by
- 106
- References
- 70
- OpenAlex
- https://openalex.org/W1970678618
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:46386201
Keywords
Vascular endothelial growth factor, Angiogenesis, Trastuzumab, Cancer research, Medicine
References
- Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.
- Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF
- Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.
- Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity.
- Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin.
- Clinical applications of angiogenic growth factors and their inhibitors
- Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
- Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients.
- Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment.
- Tumor angiogenesis in node-negative breast carcinomas — relationship with epidermal growth factor receptor, estrogen receptor, and survival
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
- Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients.
- Vascular Endothelial Growth Factor Up-regulation via p21-activated Kinase-1 Signaling Regulates Heregulin-β1-mediated Angiogenesis*
- Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells
- Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat
- HER‐2/neu Signal Transduction in Human Breast and Ovarian Cancer
- Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours
- Vascular endothelial growth factor is a secreted angiogenic mitogen.
- Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression
- The biology of vascular endothelial growth factor.
Cited by
- Signal transduction and apoptosis pathways as therapeutic targets.
- HERe-2 stay: the continuing importance of translational research in breast cancer.
- Zirconium-89 for positron emission tomography and hydroxamate resin column for gallium-68 generator
- Biology of the epidermal growth factor receptor family.
- Polypeptide growth factors and their receptors.
- Angiosarcome du sein : à propos de deux cas
- Viruses and Apoptosis
- Development of drug conjugates for cancer therapy and evaluation of dual sirna silencing effect on breast cancer growth and invasion
- Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets
- Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
- Targeted therapy for cancer
- Trastuzumab in the management of early and advanced stage breast cancer
- Systems Analysis Of Core Architectures Regulating Cellular Responses Under Stress In Eukaryotes
- HER-2/neu Cancer Vaccines: Present Status and Future Prospects
- HER2-Overexpressing Metastatic Breast Cancer: The Role of Trastuzumab Regimens
- Acute Tumor Lysis Syndrome Induced by Rituximab in Diffuse Large B-Cell Lymphoma
- Targeted Endoscopic Imaging
- Current status of anti-her2 therapies: predicting and overcoming herceptin resistance
- The role of HER2 in cancer therapy and targeted drug delivery
- Her-2 targeted therapy: Beyond breast cancer and trastuzumab
Related papers
- Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells
- Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2)- and protein kinase C-alpha/epsilon (PKCalpha/epsilon)-dependent cytoprotective signaling pathway and is inhibited by cyclosporin A.
- Transforming Growth Factor 1 Down-regulates Vascular Endothelial Growth Factor Receptor 2/flk-1 Expression in Vascular Endothelial Cells (*)
- Effect of PTK787 on Expression of VEGF and VEGFR-2 mRNA in Myeloid Leukemia
- Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy.
- Ligand-induced Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) Heterodimerization with VEGFR-2 in Primary Lymphatic Endothelial Cells Regulates Tyrosine Phosphorylation Sites*
- Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo.
- Heterotrimeric G alpha q/G alpha 11 proteins function upstream of vascular endothelial growth factor (VEGF) receptor-2 (KDR) phosphorylation in vascular permeability factor/VEGF signaling.
- Altered expression of vascular endothelial growth factor, vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, and Soluble Fms-like Tyrosine Kinase-1 in peripheral blood mononuclear cells from normal and preeclamptic pregnancies
- Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2